Professor Matthew Kiernan

For example?

Well, any pharma company.

So examples that we're working with very closely include Roche Diagnostics based in Switzerland, Eli Lilly or Lilly Pharma United States.

They're key, Teva, are key partners for us to drive our research programs.

But the beauty about having an industry partner is you're more likely to have what we call impact and translation.

So in other words, your discoveries are going to make it out to the patient, to the clinic,

And that's why the health district and the university are engaged, because they want to see better health outcomes.

So you're much more likely to get that if you have an industry partner.

Now, the other key way that Neura has been surviving has been the support of the community.

And we've been very lucky to have, you know, fantastic philanthropic support.

And there have been individuals who funded whole programs and, you know, developments of the building.

Margaret Ainsworth is responsible for the main building at Neura.

But I think we're starting to see that the community is investing in research with the desire to have better health outcomes.

And it's really – it's great to see.

So vascular relates to the blood vessels, and dementia generally means problems with memory and cognition.

And the brain is made up of nerves, neurons, that has lining on it.

And the lining, the myelin, is supplied.

The lining, which is called myelin, is built through cholesterol and apolipoproteins and all of those sort of bio...

biochemical processes, but it needs a vascular supply.

It needs a blood supply.